pharmaceutical policy in china ahpp walter h shorenstein asia pacific research center asia health policy program stanford university fsi centers & programs research centers center on democracy development and the rule of law center for international security and cooperation center on food security and the environment stanford health policy the europe center walter h shorenstein asia pacific research center research programs program on energy and sustainable development rural education action program educational programs stanford program on international and cross cultural education inter university center for japanese language studies ford dorsey program in international policy studies affiliated programs center for innovation in global health research areas and projects by topic by region publications people events upcoming recent podcasts & video news recent archive about ahpp about the program annual report map & directions contact us about fsi support fsi quick links podcasts & video postdoctoral fellowship in comparative health policy developing asia health policy fellowship asia health policy program working paper series community asia pacific health policy forum publications send by email share online share on facebook share on twitter share on google pharmaceutical policy in china journal article authors qiang sun shandong university michael a santoro rutgers university qingyue meng shandong university caitlin liu rutgers university karen eggleston stanford university published by health affairs vol 27 no 4 page s 1042 1050 7 2008 contradictory goals plague china's pharmaceutical policy the government wants to develop the domestic pharmaceutical industry and has used drug pricing to cross subsidize public hospitals yet the government also aims to control pharmaceutical spending through price caps and profit margin regulations to guarantee access even for poor patients the resulting system has distorted market incentives increased consumer cost and financially rewarded inappropriate prescribing thus undermining public health though pharmaceuticals account for about half of total healthcare expenditures in china representing 43 of expenditure per inpatient episode and 51 of expenditure per outpatient visit some essential medicines are unavailable or of questionable quality download html+ go to site external http content healthaffairs org cg parent research health service delivery in the asia pacific ownership payment incentives and chronic disease management historical development of healthcare institutions in east asia topics health care institutions china search ahpp publications everything publication news comparative pharmaceutical policy and prescribing cultures july 17 2008 shorenstein aparc news publications of interest prescribing cultures and pharmaceutical policy in the asia pacific karen eggleston shorenstein aparc distributed by brookings institution press 2009 pdf+ buy+ cover pharmaceutical price regulation macro level evidence from china between 1997 and 2008 binzhen wu qiong zhang xue qiao asia health policy program working paper 26 2012 pdf+ cover support map & directions contact rss+ rss xml feeds freeman spogli institute for international studies encina hall 616 serra st stanford ca 94305 6055 tel 650 725 2429 fax 650 725 2592 mail code 6055
